← Back to Clinical Trials
Recruiting NCT06733584

NCT06733584 Meeting the Needs of Young Hispanic Autistic Children

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06733584
Status Recruiting
Phase
Sponsor The University of Texas at Dallas
Condition Autism
Study Type INTERVENTIONAL
Enrollment 200 participants
Start Date 2025-09-22
Primary Completion 2028-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Months
Max Age 42 Months
Study Type INTERVENTIONAL
Interventions
Culturally and Linguistically Responsive Pathways Parent-Mediated Intervention without Mutual GazeCulturally and Linguistically Responsive Pathways Parent-Mediated Intervention

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 200 participants in total. It began in 2025-09-22 with a primary completion date of 2028-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Purpose of the Study: The goal of this clinical trial is to find out if a technique called the "mutual gaze procedure" used in a Culturally and Linguistically Responsive adaptation of Pathways Early Intervention (CLR-Pathways) is the key to improving social communication, language, and everyday skills in young (18-42 months) Hispanic autistic children experiencing low income. What Will Happen: Researchers will compare two versions of CLR-Pathways. * Version 1: Includes mutual gaze strategies. * Version 2: Does not include mutual gaze strategies. What to Expect: Participants will: * Attend 16 sessions (or 18 weeks if there are cancellations) of Pathways Intervention, each lasting 1.5 hours. * Come to the clinic for a developmental check-up three times: before starting Pathways, right after completing Pathways, and three months after finishing Pathways.

Eligibility Criteria

Inclusion Criteria: * Children must be from a Hispanic family experiencing low income, defined as having an income-to-needs ratio of \< 320% of the federal poverty level, determined by their household size * Children must be between 18-42 months old at the start of the study * Children must have no other known neurological or genetic concerns or disorders determined by parent report * Children must receive a Calibrated Severity Score (CSS) of 4 or higher on the Autism Diagnostic Observational Schedule-2 (ADOS-2) administered by a qualified bilingual assessment associate * Families must have a primary home language of English and/or Spanish Exclusion Criteria: * Children who are from a family that is not Hispanic and/or does not have an income-to-needs ratio of \< 320% of the federal poverty level, determined by their household size * Children younger than 18 months or older than 42 months at the start of the study * Children whose parents report they have any other known neurological or genetic concerns or disorders * Children who receive a Calibrated Severity Score (CSS) lower than 4 on the ADOS-2 * Families who do not have English or Spanish as a primary home language

Contact & Investigator

Central Contact

Pamela Rollins, EdD

✉ rollins@utdallas.edu

📞 972-883-3153

Principal Investigator

Pamela Rollins, EdD

PRINCIPAL INVESTIGATOR

The University of Texas at Dallas

Frequently Asked Questions

Who can join the NCT06733584 clinical trial?

This trial is open to participants of all sexes, aged 18 Months or older, up to 42 Months, studying Autism. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06733584 currently recruiting?

Yes, NCT06733584 is actively recruiting participants. Contact the research team at rollins@utdallas.edu for enrollment information.

Where is the NCT06733584 trial being conducted?

This trial is being conducted at Lawrence, United States, Dallas, United States, Richardson, United States.

Who is sponsoring the NCT06733584 clinical trial?

NCT06733584 is sponsored by The University of Texas at Dallas. The principal investigator is Pamela Rollins, EdD at The University of Texas at Dallas. The trial plans to enroll 200 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology